Medical and Experimental Mycology Group, Corporación para Investigaciones Biológicas, Medellín, Colombia.
Hospital General de Medellín, Medellín, Colombia.
J Pediatric Infect Dis Soc. 2021 Mar 26;10(2):151-154. doi: 10.1093/jpids/piaa038.
Candida auris is an emerging multidrug-resistant yeast that can cause invasive infections and healthcare-associated outbreaks. Here, we describe 34 cases of pediatric C. auris bloodstream infections (BSIs) identified during July 2014-October 2017 in 2 hospitals in Colombia.
We conducted a retrospective review of microbiology records for possible C. auris cases in 2 hospitals in Barranquilla and Cartagena. BSIs that occurred in patients aged <18 years confirmed as C. auris were included in this analysis.
We identified 34 children with C. auris BSIs. Twenty-two (65%) patients were male, 21% were aged <28 days, 47% were aged 29-365 days, and 32% were aged >1 year. Underlying conditions included preterm birth (26%), being malnourished (59%), cancer (12%), solid-organ transplant (3%), and renal disease (3%). Eighty-two percent had a central venous catheter (CVC), 82% were on respiratory support, 56% received total parenteral nutrition (TPN), 15% had a surgical procedure, and 9% received hemodialysis. Preinfection inpatient stay was 22 days (interquartile range, 19-33 days), and in-hospital mortality was 41%.
Candida auris affects children with a variety of medical conditions including prematurity and malignancy, as well as children with CVCs and those who receive TPN. Mortality was high, with nearly half of patients dying before discharge. However, unlike most other Candida species, C. auris can be transmitted in healthcare settings, as suggested by the close clustering of cases in time at each of the hospitals.Candida auris is an emerging multidrug-resistant yeast that can cause invasive infections and healthcare-associated outbreaks. This report describes 34 cases of pediatric C. auris bloodstream infections, identified in two hospitals in Colombia, South America.
耳念珠菌是一种新兴的耐多药酵母,可引起侵袭性感染和与医疗保健相关的暴发。在这里,我们描述了 2014 年 7 月至 2017 年 10 月期间在哥伦比亚两家医院发现的 34 例儿科耳念珠菌血流感染(BSI)病例。
我们对巴兰基亚和卡塔赫纳的两家医院的微生物学记录进行了回顾性审查,以确定可能的耳念珠菌病例。将在年龄<18 岁的患者中发生并经证实为耳念珠菌的 BSI 病例纳入本分析。
我们共发现 34 例儿童耳念珠菌 BSI。22 例(65%)患者为男性,21%患者年龄<28 天,47%患者年龄 29-365 天,32%患者年龄>1 岁。基础疾病包括早产(26%)、营养不良(59%)、癌症(12%)、实体器官移植(3%)和肾脏疾病(3%)。82%的患者有中心静脉导管(CVC),82%的患者需要呼吸支持,56%的患者接受全胃肠外营养(TPN),15%的患者接受了手术,9%的患者接受了血液透析。感染前住院时间为 22 天(四分位距,19-33 天),院内死亡率为 41%。
耳念珠菌影响包括早产和恶性肿瘤在内的各种疾病的儿童,也影响有 CVC 和接受 TPN 的儿童。死亡率很高,近一半的患者在出院前死亡。然而,与大多数其他念珠菌属不同,耳念珠菌可以在医疗机构中传播,这两家医院的病例在时间上非常接近,表明了这一点。